This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cell Therapeutics To Host Analyst And Investor Meeting On Advances And Existing Challenges In The Treatment Of Myelofibrosis With Live Webcast

SEATTLE, Jan. 16, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that CTI will provide a live audio and slide webcast of its analyst and investor meeting to be held on January 23 in New York.  Expert speakers will focus on advances in treatment using JAK inhibitors and existing challenges in treating myelofibrosis patients. Guest speakers include:

Ross L. Levine, M.D., Associate Member at Memorial Sloan-Kettering Cancer Center in the Human Oncology and Pathogenesis Program and Leukemia Service, Associate Professor of Medicine at Weill Cornell Medical College

Srdan Verstovsek, M.D., Ph.D., Professor, Leukemia Department, Division of Cancer Medicine, Chief, Section for Myeloproliferative Neoplasms, Leukemia Department, and Director, Clinical Research Center for MPNs, at The University of Texas MD Anderson Cancer Center

CTI recently initiated a Phase 3 clinical trial, known as PERSIST-1, for pacritinib, CTI's investigational JAK2 inhibitor that is being evaluated for the treatment of patients with myelofibrosis.  

Webcast Details

Date: Wednesday, January 23, 2013

Time: 9:00 a.m. Eastern / 6:00 a.m. Pacific / 3:00 p.m. Central European time to 10:30 a.m. Eastern/ 7:30 a.m. Pacific/ 4:30 p.m. Central European time

Live webcast access: Go to The audio presentation with slides will be available approximately two hours after the end of the meeting.

About Pacritinib

Pacritinib is an oral, once-a-day, tyrosine kinase inhibitor (TKI) with dual activity against JAK2 and FLT3.  The JAK family of enzymes are a central component in signal transduction pathways, which are critical to normal blood cell growth and development as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have been shown to be directly related to the development of a variety of blood related cancers including myeloproliferative neoplasms, leukemia and lymphoma.  Pacritinib may offer an advantage over other JAK inhibitors through effective treatment of symptoms while having less treatment-emergent thrombocytopenia and anemia than has been seen in currently approved and in-development JAK inhibitors.  Pacritinib has demonstrated encouraging results in Phase 1 and 2 studies for patients with myelofibrosis.  Pacritinib has orphan drug designation in the U.S. and Europe.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,013.43 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs